Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Drug: Daraxonrasib for kRAS Mutated Pancreatic Cancer
In this phase 1-2 study involving patients with previously treated RAS-mutated pancreatic ductal adenocarcinoma, daraxonrasib administered at up to 300 mg daily demonstrated antitu
New Reference: SubQ Daratumumab with VCd for Newly Diagnosed Amyloidosis
In this phase 3 trial of newly diagnosed AL amyloidosis, adding subcutaneous daratumumab to VCd significantly improved hematologic complete response rate. The combination also impr
New Reference: Tucatinib for Leptomeningeal Metastasis
This phase 2 study in patients with HER2-positive breast cancer and leptomeningeal metastases showed that tucatinib, trastuzumab, and capecitabine achieved a median overall surviva
New Protocol: Trabectedin Olaparib Combo for Soft Tissue Sarcoma
This phase II randomized study in advanced soft tissue sarcoma patients found a marginal progression-free survival benefit with trabectedin plus olaparib compared to trabectedin al
New Drug: Setidegrasib for kRAS G12D Mutated Cancers
This phase 1 study demonstrated that setidegrasib, a first-in-class selective KRAS G12D-targeted protein degrader, has antitumor activity in patients with previously treated advanc
New Drug: Oral Paclitaxel for Metastatic Breast Cancer
In this multinational phase III trial, oral paclitaxel DHP107 demonstrated non-inferior progression-free survival compared to intravenous weekly paclitaxel in patients with HER2-ne
New Reference: Nivolumab for 1st Line Hodgkin Lymphoma
In this phase 3 trial of patients with advanced-stage classic Hodgkin’s lymphoma, nivolumab combined with AVD chemotherapy resulted in significantly improved progression-free sur
New Reference: Fixed-Duration Treatment of CLL
This phase 3 trial in untreated chronic lymphocytic leukemia patients showed that fixed-duration treatment with venetoclax combinations was noninferior to continuous ibrutinib in p
New Protocol: Durvalumab – Olaparib for Ovarina Cancer
This phase III DUO-O study in newly diagnosed advanced-stage ovarian cancer patients without tumor BRCA mutation showed that adding durvalumab plus olaparib to carboplatin/paclitax
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.